Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.9252W HIGH $9.75
Volume
1.12 M
Value Traded
31.58 M
Short % Float
23.36%
Days to Cover
13.9
+1.67%Week
-18.66%1 Month
-31.61%3 Month
-0.11%6 Month
-65.01%5 Year
-52.8%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.59 B
EPS (TTM)
-0.43
P/E Ratio
-
Ent. Value
1.43 B
Total Shares
351.08 M
Float Shares
251.98 M
Insiders
28.44%
Institutions
56.20%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
NUVB Catalyst Timeline
Dated clinical, regulatory and corporate events for Nuvation Bio Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nuvation Bio Inc.
224Total events
15Upcoming
53Tier-1 (high impact)
2020 to 2033Coverage
Upcoming catalysts 2
Event history 50
▲Supplemental ApprovalIBTROZIApprovedFDA Decision
FDA approves sNDA for IBTROZI (taletrectinib) with updated DOR in TKI-naïve ROS1+ NSCLC
ROS1-positive non-small cell lung cancersource ↗
▲Poster PresentationIBTROZIApprovedPresentation
New subgroup analyses from TRUST-I and TRUST-II presented at IASLC 2026 WCLC
advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC)source ↗
▲Subgroup AnalysisIBTROZIApprovedClinical Data
Consistent response rates regardless of prior chemotherapy exposure in TKI-naive patients
advanced ROS1-positive (ROS1+) NSCLCsource ↗
▲Safety Data UpdateIBTROZIApprovedClinical Data
Long-term follow-up shows manageable safety profile with no new safety signals
advanced ROS1-positive (ROS1+) NSCLCsource ↗
▲Poster PresentationIBTROZIApprovedPresentation
New subgroup analyses from TRUST-I and TRUST-II presented at IASLC 2026 WCLC
advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC)source ↗
▲Subgroup AnalysisIBTROZIApprovedClinical Data
Consistent efficacy between CD74 and non-CD74 ROS1 fusion partners
advanced ROS1+ NSCLCsource ↗
▲Safety Data UpdateIBTROZIApprovedClinical Data
Long-term follow-up showed manageable safety profile with no new safety signals
advanced ROS1+ NSCLCsource ↗
●Enrollment UpdateSafusidenibTrial
Pivotal Phase 3 SIGMA study enrollment underway
IDH1-mutant astrocytoma with high-risk featuressource ↗
▲Full ResultsSafusidenibClinical Data
Updated data from Phase 2 J201 study announced
IDH1-mutant gliomasource ↗
▲Fast Track DesignationSafusidenibDesignation
FDA granted Fast Track Designation for safusidenib
IDH1-mutant gliomasource ↗
◆Oral PresentationTaletrectinibApprovedPresentation
Comparative Efficacy of Taletrectinib Versus First-Generation TKIs in TKI-Naïve ROS1+ Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison
ROS1+ Non-Small Cell Lung Cancersource ↗
▲Full ResultsSafusidenibClinical Data
Updated Phase 2 data with 38.8 months follow-up: ORR 52%, 36-month PFS rate 79%
IDH1-mutant gliomasource ↗
◆Trial InitiationSafusidenibTrial
Initiation of Phase 3 G307 study in newly diagnosed grade 2 IDH1-mutant glioma outside U.S.
IDH1-mutant gliomasource ↗
▼Equity OfferingCorporate
Full exercise of greenshoe option in $287.5M convertible senior notes offering
▲Full ResultsSafusidenibClinical Data
Updated positive long-term follow-up data from Phase 2 J201 study of safusidenib
IDH1-mutant gliomasource ↗
▲Trial InitiationSafusidenibTrial
Initiated Phase 2 study G209 in vorasidenib-progressed IDH1-mutant glioma in U.S.
IDH1-mutant gliomasource ↗
●Equity OfferingCorporate
Received $36.5M net proceeds from exercise of convertible notes overallotment option
●Debt Royalty FinancingCorporate
Completed public offering of 0.75% Convertible Senior Notes with net proceeds ~$279.1M
▲Product LaunchIBTROZIApprovedPost-Market
IBTROZI net product revenue of $23.2M in Q2 2026
ROS1+ NSCLCsource ↗
▲MHRA MilestoneTaletrectinibApprovedEx-US Regulatory
MHRA validates Marketing Authorisation Application for taletrectinib in the UK
advanced ROS1-positive non-small cell lung cancersource ↗
◆Oral PresentationPresentation
Nuvation Bio to present at Jefferies Global Healthcare Conference
▲Other Regulator MilestoneTaletrectinibApprovedEx-US Regulatory
MHRA validated MAA for taletrectinib
ROS1+ NSCLCsource ↗
▲EMA ValidationTaletrectinibApprovedEx-US Regulatory
MHRA validated MAA for taletrectinib
ROS1+ NSCLCsource ↗
▲MHRA MilestoneTaletrectinibApprovedEx-US Regulatory
MHRA validates MAA for taletrectinib in the UK
ROS1-positive non-small cell lung cancersource ↗
◆Oral PresentationPresentation
TD Cowen's 7th Annual Oncology Innovation Summit virtual fireside chat
◆Oral PresentationPresentation
2026 RBC Capital Markets Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
H.C. Wainwright 4th Annual BioConnect Investor Conference fireside chat
◆Oral PresentationPresentation
Bank of America Securities 2026 Healthcare Conference fireside chat
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Business Update Conference Call
▲Partnership / LicenseSafusidenibCorporate
Acquisition of Japan rights to safusidenib from Daiichi Sankyo
IDH1-mutant gliomasource ↗
▲FDA Filing AcceptedIBTROZIApprovedRegulatory Filing
FDA accepted sNDA for IBTROZI with target action date Jan 4, 2027
ROS1+ NSCLCsource ↗
▲Oral PresentationIBTROZIApprovedPresentation
Patient-reported outcomes from TRUST-II presented at ASCO 2026
ROS1+ NSCLCsource ↗
▲Manufacturing MilestoneIBTROZIApprovedCMC / Inspection
Completed process technology transfer to Thermo Fisher for U.S. manufacturing
ROS1+ NSCLCsource ↗
●Oral PresentationTaletrectinibApprovedPresentation
Updated data from TRUST clinical program presented at AACR Annual Meeting
advanced ROS1-positive non-small cell lung cancersource ↗
▲Full ResultsTaletrectinibApprovedClinical Data
Updated TRUST-I results published in Journal of Clinical Oncology
advanced ROS1-positive NSCLCsource ↗
●PublicationTaletrectinibApprovedPresentation
Updated results from TRUST-I published in Journal of Clinical Oncology
advanced ROS1-positive non-small cell lung cancersource ↗
▲Oral PresentationIBTROZIApprovedPresentation
Updated pooled results from TRUST-I and TRUST-II presented at AACR 2026
ROS1+ NSCLCsource ↗
▲PublicationIBTROZIApprovedPresentation
Updated TRUST-I results published in Journal of Clinical Oncology
ROS1+ NSCLCsource ↗
▲Partnership / LicenseSafusidenibCorporate
Acquired Japan rights to safusidenib from Daiichi Sankyo
IDH1-mutant gliomasource ↗
▲Product LaunchIBTROZIApprovedPost-Market
IBTROZI net product revenues of $18.5 million in Q1 2026
ROS1-positive non-small cell lung cancersource ↗
▲EMA ValidationTaletrectinibApprovedEx-US Regulatory
EMA validates Marketing Authorisation Application for taletrectinib
advanced ROS1-positive non-small cell lung cancersource ↗
●EU MAA SubmissionTaletrectinibApprovedEx-US Regulatory
MAA submitted to EMA for taletrectinib
advanced ROS1-positive non-small cell lung cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How NUVB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-16 | Ibtrozi (taletrectinib adipate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 22%
Micro Cap(rank 145 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| IBTROZI |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Safusidenib Small moleculeNCT07712757 | Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation | Phase 3 | NOT YET_RECRUITING | 140 | Mar 1, 2032 | ||||||
| Safusidenib Small moleculeNCT05303519 | Glioma | Phase 3 | RECRUITING | 365 | Dec 1, 2030 | ||||||
| Safusidenib Small moleculeNCT07703436 | Grade 2 IDH1-mutant Glioma | Phase 2 | RECRUITING | 40 | Mar 1, 2032 | ||||||
| NUV-1511 Small moleculeNCT06334432 | Advanced Solid Tumor | Phase 1 | ACTIVE NOT_RECRUITING | 466 | Oct 1, 2027 | ||||||
| Taletrectinib Small moleculeMarketedNCT04919811 | Non Small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 764 | Dec 1, 2027 | ||||||
| Multiple administration of omeprazole Single administration of AB-106 Small moleculeMarketedNCT05609929 | Undisclosed | Phase 1 | COMPLETED | 24 | Jan 20, 2023 | ||||||
| Taletrectinib Small moleculeMarketedNCT05357911 | Solid Tumor | Phase 1 | COMPLETED | 72 | Dec 3, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every NUVB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IBTROZI BreakthroughPriority | advanced ROS1-positive non-small cell lung cancer (NSCLC) | 2026-09-15 | ORR TKI naive prior chemo: 90.0%; ORR TKI naive no prior chemo: 89.8%; DOR TKI naive prior chemo: 48.3 months; DOR TKI naive no prior chemo: 54.3 months; ORR CD74 fusion: 89.5%; ORR non CD74 fusion: 88.9%Read More | Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hattersley GaryOfficer (CHIEF SCIENTIFIC OFFICER) | Option | 100,000 100,000 held | $1.87 | 08/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NUVB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.9 % (28.6 %) | 18.74 M | 3.30 M | 4.76% ( 150.00 K) |
NUVB Institutional Ownership Trends
NUVB Short Interest
Shares sold short, counted twice a month.
23.36%
Short % of Float
of tradable shares sold short
58.9M
Shares Sold Short
+1.2% vs prior count
13.9 Very high
Days to Cover
trading days of normal volume to buy every short share back
4.2M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NUVB ranks across every disease it competes in
Competitive Position is a premium feature
See how NUVB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNUVB News
NUVBNuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
Nuvation Bio Inc. will host a conference call on November 4, 2026, to discuss its third quarter financial results and business updates. The call will be accessible to investors and the public via a live webcast. The company aims to develop impactful cancer therapies and has a diverse pipeline.
Read more →NUVB▲ +5%on this news
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio has received FDA approval for a supplemental New Drug Application for IBTROZI (taletrectinib), which now includes an updated median duration of response of 49.7 months for TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer. The approval, which came four months early, confirms the drug's safety profile with no new safety signals identified. This update is significant for patients and physicians, providing clarity on treatment expectations.
Read more →NUVBNuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
Nuvation Bio presented new analyses at the 2026 World Conference on Lung Cancer, demonstrating that IBTROZI (taletrectinib) maintains consistent efficacy in advanced ROS1-positive non-small cell lung cancer (NSCLC) across various patient subgroups. The data from the TRUST-I and TRUST-II studies showed similar response rates and duration of response, regardless of prior chemotherapy exposure or ROS1 fusion partner. These findings support early biomarker testing and timely transition to targeted therapy.
Read more →NUVBNuvation Bio to Participate in Upcoming Investor Conferences
Nuvation Bio Inc. will participate in upcoming investor conferences, including the Citi's 2026 Biopharma Back to School Conference and the 2026 Cantor Global Healthcare Conference. CEO David Hung and CFO Philippe Sauvage will lead discussions and one-on-one meetings. Live webcasts will be available on their website.
Read more →NUVB▼ -5.9%on this news
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
Nuvation Bio has received FDA Fast Track Designation for safusidenib, an oral inhibitor targeting IDH1-mutant glioma. This designation aims to expedite the regulatory review process, contingent on positive clinical data. The ongoing Phase 3 SIGMA study is expected to evaluate safusidenib's effectiveness as a maintenance therapy. The drug has shown encouraging results in earlier studies, indicating its potential to meet critical patient needs.
Read more →NUVBNuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio reported strong financial results for Q2 2026, achieving $31.7 million in total revenue, with $23.2 million from IBTROZI. The drug is now the most prescribed ROS1 TKI, showing a 30% growth in TKI-naïve patients. Additionally, positive long-term data for safusidenib was announced, expanding its clinical program. Despite a net loss of $62.8 million, the company maintains a robust balance sheet.
Read more →NUVBNuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Nuvation Bio announced that it will present new subgroup analyses of long-term data from its Phase 2 TRUST-I and TRUST-II studies for IBTROZI (taletrectinib) at the upcoming WCLC and ESMO congresses. These analyses will focus on the efficacy and safety of IBTROZI in patients with advanced ROS1-positive non-small cell lung cancer. The findings aim to reinforce the drug's potential as a standard treatment option across various patient subgroups.
Read more →NUVBNuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Nuvation Bio Inc. will host a conference call on August 6, 2026, to discuss its financial results for Q2 2026 and provide business updates. Investors and the public can access the live webcast and participate via a conference call. The company, founded in 2018, focuses on developing impactful cancer therapies.
Read more →NUVB▲ +7.9%on this newsshared move
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
Nuvation Bio has announced positive updated Phase 2 data for safusidenib, showing a confirmed objective response rate of 52% and a 36-month progression-free survival rate of 79%. The company is expanding its clinical program with two new studies: a Phase 3 study for newly diagnosed grade 2 glioma patients outside the U.S. and a Phase 2 study for patients whose glioma has progressed after treatment with vorasidenib in the U.S. The long-term data supports the efficacy and safety of safusidenib.
Read more →NUVBNuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Nuvation Bio Inc. announced the full exercise of its Greenshoe option, raising an additional $37.5 million in a convertible senior notes offering, totaling $287.5 million. The company plans to use the net proceeds of approximately $277.6 million for general corporate purposes, including working capital and operating expenses. The offering was conducted under a registration statement with the SEC.
Read more →NUVBNuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
Nuvation Bio announced that the Medicines and Healthcare products Regulatory Agency in the U.K. has validated the Marketing Authorisation Application for taletrectinib, an oral treatment for advanced ROS1-positive non-small cell lung cancer. This follows a similar validation by the European Medicines Agency. Taletrectinib has already been approved in the U.S., China, and Japan, and aims to expand access for patients in the U.K.
Read more →NUVBNuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
Nuvation Bio has announced the pricing of an upsized offering of $250 million in convertible senior notes due in 2032. The offering, initially set at $200 million, is expected to close on June 30, 2026. Proceeds will be used to repay existing debt and for general corporate purposes. The notes will have a 0.75% interest rate and are convertible under specific conditions.
Read more →NUVB▼ -10.1%on this newsshared move
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
Nuvation Bio has announced a proposed offering of $200 million in Convertible Senior Notes due in 2032, with an option for underwriters to purchase an additional $30 million. The proceeds will be used for various corporate purposes, including repaying existing loans. The offering is subject to market conditions and will include capped call transactions to mitigate potential dilution.
Read more →NUVBNuvation Bio to Present at the Jefferies Global Healthcare Conference
Nuvation Bio Inc. will present at the Jefferies Global Healthcare Conference on June 3, 2026. CEO David Hung and CFO Philippe Sauvage will participate in a fireside chat, which will be available via live webcast. The company aims to address major challenges in cancer treatment with its diverse pipeline of therapies.
Read more →NUVBNuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio reported strong financial results for the first quarter of 2026, with $18.5 million in net product revenues from IBTROZI, their ROS1 inhibitor. The company noted continued adoption in TKI-naïve patients and impressive long-term response durability exceeding four years. Additionally, Nuvation secured exclusive global rights to safusidenib, which is intended to advance the treatment options for IDH1-mutant glioma. Despite rising research and administrative costs, the company remains on a solid financial footing, with over $533 million in cash and assets.
Read more →NUVB▼ -6.7%on this news
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Nuvation Bio announced that taletrectinib (IBTROZI) has been included in the NCCN Guidelines for CNS cancers as a recommended systemic therapy for ROS1-positive non-small cell lung cancer patients with brain metastases. This addition follows its previous recognition as a preferred agent for NSCLC. The drug has shown significant efficacy in treating brain metastases, highlighting its importance in addressing the needs of this patient population.
Read more →NUVBNuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
Nuvation Bio Inc. will host a conference call on May 4, 2026, to discuss its Q1 financial results and business updates. The event will be accessible via a live webcast and phone call. Nuvation Bio is dedicated to developing impactful cancer therapies, with a pipeline that includes several innovative treatments.
Read more →NUVBEisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Eisai and Nuvation Bio have announced that the European Medicines Agency has validated their Marketing Authorisation Application for taletrectinib, a treatment for advanced ROS1-positive non-small cell lung cancer. This application follows approvals in the U.S., China, and Japan, with plans for additional filings in other regions. The companies aim to make this therapy available to patients in Europe, pending the review process.
Read more →NUVB▼ -25.3%on this news
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Nuvation Bio reported strong financial results for Q4 and full year 2025, highlighting the successful launch of IBTROZI, which has rapidly gained adoption. The company also announced positive Phase 2 results for safusidenib in treating IDH1-mutant glioma. Despite a net loss of $36.6 million in Q4, Nuvation maintains a robust cash position of $529.2 million and is expanding its collaboration with Eisai to enhance global access to IBTROZI.
Read more →About Nuvation Bio Inc.
Headquarters1500 BROADWAY, NEW YORK, NY, 10036
BIOPHARMAWATCH ELITE PLUS
Trade the next NUVB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime